Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Divergent BRAF Inhibitor Resistance Mechanisms Revealed through Epigenetic Mapping.

The Journal of investigative dermatology - 1 May 2023

Kang Yuanyuan, Ji Zhenyu, Li He, Tsao Hensin

Abstract excerpt

Although tremendous progress has been made in targeted and immune-based treatments for advanced melanoma, there remains a substantial therapeutic failure rate. For patients with BRAF(V600)-mutant melanomas, resistance to BRAF inhibitors remains a significant survival hurdle. Although multiple compensatory mechanisms to bypass BRAF blockade have been discovered, the epigenetic patterns are still poorly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Epigenesis, Genetic
Share to Indoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Source

Identifiers

PMID: 36529262
DOI: 10.1016/j.jid.2022.03.039

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Divergent BRAF Inhibitor Resistance Mechanisms Revealed through Epigenetic Mapping.PMID 36529262Read ↗

BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Semantic proximity Read ↗

Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional Profiles.Semantic proximity Read ↗

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor TherapySemantic proximity Read ↗

Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted TherapiesSemantic proximity Read ↗

Enhancer Reprogramming in Melanoma Immune Checkpoint Therapy ResistanceSemantic proximity Read ↗

Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic PlasticitySemantic proximity Read ↗

Epigenetic modifiers to enhance the efficacy of immune checkpoint inhibitors for the treatment of melanomaSemantic proximity Read ↗

Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanomaSemantic proximity Read ↗

CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-resistant Melanoma.Semantic proximity Read ↗

Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1RSemantic proximity Read ↗

Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary ConvergenceSemantic proximity Read ↗

Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.